Masimo Co. (NASDAQ:MASI) Receives $144.67 Average PT from Analysts

Masimo Co. (NASDAQ:MASI - Get Free Report) has received an average rating of "Moderate Buy" from the seven ratings firms that are currently covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $144.67.

MASI has been the topic of a number of research reports. Needham & Company LLC reissued a "hold" rating on shares of Masimo in a report on Wednesday, August 7th. Piper Sandler boosted their target price on Masimo from $160.00 to $165.00 and gave the company an "overweight" rating in a report on Wednesday, August 7th.

Institutional Trading of Masimo

Several hedge funds have recently modified their holdings of the business. Riverview Trust Co acquired a new position in Masimo during the first quarter worth $25,000. GAMMA Investing LLC increased its holdings in shares of Masimo by 75.0% in the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 111 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Masimo by 851.6% in the fourth quarter. EverSource Wealth Advisors LLC now owns 295 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 264 shares during the period. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider's stock valued at $44,000 after purchasing an additional 200 shares during the period. Finally, Parallel Advisors LLC boosted its holdings in Masimo by 48.3% during the fourth quarter. Parallel Advisors LLC now owns 445 shares of the medical equipment provider's stock worth $52,000 after buying an additional 145 shares in the last quarter. 85.96% of the stock is owned by institutional investors and hedge funds.

Masimo Stock Performance

MASI traded up $0.75 during trading on Thursday, hitting $117.13. 219,602 shares of the stock were exchanged, compared to its average volume of 657,746. The company has a quick ratio of 1.31, a current ratio of 2.31 and a debt-to-equity ratio of 0.62. Masimo has a 1-year low of $75.22 and a 1-year high of $153.93. The stock has a fifty day moving average price of $116.44 and a two-hundred day moving average price of $126.94. The firm has a market capitalization of $6.23 billion, a P/E ratio of 79.68 and a beta of 0.97.

Masimo (NASDAQ:MASI - Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.77 by $0.09. Masimo had a net margin of 4.01% and a return on equity of 13.26%. The firm had revenue of $496.30 million during the quarter, compared to the consensus estimate of $493.92 million. During the same quarter in the prior year, the firm earned $0.62 EPS. Masimo's revenue for the quarter was up 9.0% on a year-over-year basis. As a group, sell-side analysts predict that Masimo will post 3.63 earnings per share for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.